Home Medizin Ubiquigent schließt Vereinbarung mit Astellas-Tochter Nanna Therapeutics

Ubiquigent schließt Vereinbarung mit Astellas-Tochter Nanna Therapeutics

von NFI Redaktion

Ubiquigent Limited (Ubiquigent) is a drug discovery and development company utilizing novel Deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need. Today, Ubiquigent announced an agreement with Nanna Therapeutics.

Under the agreement, Ubiquigent will provide Nanna access to its DUB-focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.

DUB enzymes regulate ubiquitination in the Ubiquitin-Proteasome System (UPS). Dysregulation of DUB activity is associated with many human diseases, highlighting their importance and potential for developing novel therapeutics.

Ubiquigent is the partner of choice for many leading industry and academic organizations for their drug discovery programs in protein degradation, stabilization, and cellular signal transduction. Ubiquigent has an established, specialized drug discovery platform and years of experience in using DUBs for therapeutic purposes.

The platform can be used to support the development of DUB inhibitors, DUB-targeting PROTACs, and DUBTACs in all therapeutic areas.

We are excited to announce this latest agreement and look forward to supporting the team at Nanna Therapeutics. Our platform was established to assist those looking to modulate DUB activity for therapeutic purposes and is utilized by a long list of global partners, to which we are very pleased to add Nanna Therapeutics.“

Jason Mundin, CEO of Ubiquigent

Learn more about the discovery and development platform from Ubiquigent by visiting https://www.ubiquigent.com/platform.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.